The goal of topical and cutaneous delivery is to deliver therapeutic and other substances to a desired target site in the skin at appropriate doses to achieve a safe and efficacious outcome. Normally, however, when the stratum corneum is intact and the skin barrier is uncompromised, this is limited to molecules that are relatively lipophilic, small and uncharged, thereby excluding many potentially useful therapeutic peptides, proteins, vaccines, gene fragments or drug-carrying particles. In this review we will describe how nanosystems are being increasingly exploited for topical and cutaneous delivery, particularly for these previously difficult substances. This is also being driven by the development of novel technologies, which include minimally invasive delivery systems and more precise fabrication techniques. While there is a vast array of nanosystems under development and many undergoing advanced clinical trials, relatively few have achieved full translation to clinical practice. This slow uptake may be due, in part, to the need for a rigorous demonstration of safety in these new nanotechnologies. Some of the safety aspects associated with nanosystems will be considered in this review.
Introduction
There has been great interest in nanosystem facilitated delivery of therapeutic, diagnostic, prophylactic or cosmetic substances into the skin, in which the goal is to overcome the skin barrier in a controlled manner to reach targets in various skin layers, including the stratum corneum, as well as deeper tissues, or systemically. On the other hand, nanomaterials are also applied directly to the skin, for example, when titanium or zinc oxide is used as sunscreens. Here, the intention is not to penetrate the stratum corneum, but to deliver the nanomaterials so that they remain on the skin surface. In this review, we will examine some of the various nanosystems currently in use, with particular reference to their ability to penetrate the skin barrier. Table 1 summarises the scope of the field of topical and cutaneous delivery using nanosystems and Table 2 gives a more detailed summary of the properties of some of the nanodelivery systems to be discussed later in this review. The range of particulate nanosystems under investigation is illustrated in Fig. 1 . Some of the applications of topically applied nanodelivery systems for treatment of skin disorders are listed in Table 3 .
The stratum corneum barrier problem
The skin plays a major role in protecting the body from the surrounding environment by providing a highly efficient barrier to the penetration of exogenous molecules and micro-organisms, and maintaining homeostasis by preventing excessive loss of water [38] . A simplified representation of human skin containing its major structures and cell types is illustrated in Fig. 2 . Although the location of the barrier within the skin was long debated, Scheuplein showed conclusively in 1966 that it largely resided in the stratum corneum [39] , due to its unique structure, most simply described as a series of layers of flattened corneocytes surrounded by a lipid envelope. The most likely route taken by a substance in penetrating the stratum corneum is via a tortuous pathway through the lipids surrounding the corneocytes (intercellular route) [40] , although the transcellular route though the corneocytes may be viable under certain circumstances [41] . The stratum corneum is also traversed by pilosebaceous units (hair follicles and associated sebaceous glands) and sweat glands. While the average follicular orifice area on the human skin surface is only about 0.1% of the total surface area [42] , under some circumstances these appendages may be potential routes of entry into the skin [43] , as we shall discuss later.
The fundamental question facing those who seek to develop formulations for topical or transdermal delivery is; how can a particular active be made to overcome the formidable stratum corneum barrier, so that it can be delivered to the site of action in sufficient quantities to achieve a desired therapeutic effect, with the least possible adverse effects? The range of substances that are suitable for diffusion through the stratum corneum is generally limited to those that are relatively small (b~500 Da), lipophilic (log 1-3) and water soluble [44] . Given the generally low permeation rates for most molecules, they must also be highly potent [45] . Clearly, there is a vast array of attractive prospects for topical application such as peptides, proteins, vaccines, nucleotide fragments or powerful cancer therapeutics that do not fit these criteria. This dilemma has been a major factor in the interest in nanodelivery systems that could expand the range of active molecules that are available for therapeutic or other purposes.
Solid nanoparticles (NPs)
In the early 1900s, Ehrlich introduced the concept of drug targeting using a delivery system he called 'Zauberkugeln' (Magic Bullets) [46] . This was put into practice in the 1950s and 1960s with the development of miniaturised delivery systems, focusing initially on polyacrylic beads for oral delivery, with the first nanoparticles for vaccination purposes appearing in the late 1960s [47] . By 1978, the field was sufficiently advanced for the first review article on nanoparticles as new drug delivery systems to be published [48] . In 1994, nanoparticles were defined for pharmaceutical purposes in the Encyclopaedia of Pharmaceutical Technology as "solid colloidal particles ranging in size from 1 to 1000 nm. They consist of macromolecular materials and can be used therapeutically as drug carriers, in which the active principle (drug or biologically active material) is dissolved, entrapped, or encapsulated, or to which the active principle is adsorbed or attached" [49] . Later developments saw the use of nanoparticles for intravenous cancer therapy, with Brasseur et al. reporting an enhanced efficacy of actinomycin D absorbed on polymethylcyanoacrylate nanoparticles against an experimental subcutaneous sarcoma [50] , taking advantage of their enhanced permeability and retention effects [51] . The first commercial nanoparticle product containing a drug appeared on the US market in 2005. This contained an injectable suspension of human serum albumin nanoparticles containing paclitaxel (Abraxane®, Abraxis BioScience, now Celgene Corporation, Los Angeles, CA, USA) and was indicated for the treatment of metastatic breast cancer [52] .
The first reported topical applications of nanoparticles were to the eye, when Li et al. treated albino rabbits with polymeric nanoparticles encapsulating progesterone in 1986 [53] . However, it was not until the end of the 20th century that reports on the application of nanoparticles to skin for vaccination [54] and vitamin A delivery [55] appeared in the literature. In the short time since, the topical application of a range of nanomaterials has been investigated. Of interest in this review are such materials as quantum dots, metal particles (gold, silver and beryllium), metal oxides (TiO 2 , ZnO, carbon nanotubes and organic fullerene derivatives [1, [56] [57] [58] [59] [60] [61] [62] [63] [64] . These are relevant because, as we have already seen, nanosystems are not only potential drug delivery vectors, but some have also been suspected of causing harmful effects on the skin. For instance, it has been proposed that surface-coated quantum dots could be used to carry drugs into the skin [65] . Similarly, drug-coated particles could be targeted to appendages such as hair follicles, where their payloads could be released slowly into local sites or into the systemic circulation [66] . Conversely, the unwanted penetration of Major area of concern from regulators and consumers nanoparticles through occupational or environmental exposure [64] , or through absorption of nano sunscreen substances could have toxic consequences [67] .
Factors affecting skin penetration of solid nanoparticles
The properties of nanoparticles that could influence penetration of nanoparticles through the stratum corneum, as well as potential deposition in furrows, appendages and deeper skin layers include size (both in the native state and in conjunction with associated water or other solvent molecules), shape, charge and surface properties such as coatings or functional groups, as well as their aggregation state [68] . In addition, the vehicle in which the particles are suspended can have an influence by altering the properties of the nanoparticles themselves [69] or by affecting the permeability of the stratum corneum [58] . Furthermore, the condition of the skin, including the presence of an altered or impaired barrier due to specific skin diseases may affect the degree and depth of nanoparticle penetration [70, 71] . A summary of the factors influencing the skin penetration of nanoparticles, as well as the potential routes of delivery is illustrated in Fig. 3 .
In evaluating the large volume of literature on nanoparticle skin penetration, it is important to be aware of the experimental conditions under which the studies were carried out. This is highlighted in Fig. 4 which shows the wide variation in penetration of various gold based nanoparticles through excised skin from rats [72] , pigs [73] and humans [58, 74, 75] . Fig. 4 shows that rat and pig skin was highly permeable to even large (~200 nm) particles, whereas the 161 nm gold/silica particles applied to human skin remained on the surface or penetrated into follicles [74] . Moreover, in the studies by Labouta et al., [58, 75] , human skin penetration was size and vehicle-dependent. The 6 nm particles penetrated readily from aqueous buffer or toluene, as expected for such a small diameter [68, 70] . The 15 nm particles applied in aqueous buffer, accumulated in the skin furrows, but in toluene, which could potentially damage the skin barrier, they were detected in the lower epidermis. Nanoparticles b100 nm in size are invisible, while retaining sun screening properties; Current evidence suggests they remain localized in the stratum corneum of the skin with no permeation observed in the viable epidermis [1, 2] In vitro toxicity seen in cell cultures [3] ; Controversy surrounding skin permeation.
Liquid colloidal systems Microemulsions Disruption of SC lipid organization due to the formulation components such as surfactants, co-surfactants and oils [4] .
Thermodynamically more stable compared to macroemulsions and efficient solubilization of the active in the formulation.
Stability influenced by factors such as pH & temperature changes; Potential for skin irritation due to high concentration of surfactants. Nanoemulsions Solubilization/extraction of stratum corneum lipids due to the components used in nanoemulsion, thereby decreasing resistance for drug transport [5] .
Isotropic, transparent, kinetically stable; high solubilization capacity for both lipophilic & hydrophilic drugs [6] Careful selection of formulation components essential to avoid skin irritation
Vesicular carriers
Solid Lipid nanoparticles Solid lipid nanoparticles reported to deform in shape and melt after application to skin reducing the skin barrier and causing occlusion on the skin surface favoring the penetration of the active [7, 8] .
Incorporation of lipophilic and hydrophilic drugs, low cost compared to liposomes and ease of scale-up and manufacturing. Lipid matrix composed of physiological lipids exhibiting low toxicity [9] .
Poor stability and low drug loading.
Liposomes
Numerous studies have been undertaken to elucidate the mechanism of action of liposomes. A general mode involves adhesion of the liposomes on the skin surface followed by release of the active from the liposomal structure. The phospholipids and surfactants included in the formulation may act as penetration enhancers [10] .
Ability to encapsulate a wide range of hydrophilic or hydrophobic drugs, good biocompatibility, low toxicity, and targeted delivery of drugs to the site of action [11, 12] .
Poor stability and limited penetration in the upper layers of the stratum corneum [13] .
Secosomes (combination of DOTAP, Na cholate, cholesterol, ethanol)
Leaching of stratum corneum lipids leading to migration of secosomes in the skin fissures and uptake by keratinocytes [14] .
Enhanced skin penetration due to ultradeformability [14, 15] .
Novel delivery system with limited research undertaken.
Transferosomes
Destabilization & increase in deformability by lowering interfacial tension of lipid bilayers [16] .
Elastic vesicles capable of permeating intact skin [16] .
Emulsifiers (edge activators) must be high purity to avoid risk of skin irritation & toxicity Ethosomes
Fluidization of the lipid bilayers due to an edge activator or alcohols which also enhance the deformability of the vesicles [17] .
Increase in stability and enhancement in transdermal permeation compared to conventional liposomes. High loading capacity for lipophilic drugs compared to liposomes; relatively simple & inexpensive to manufacture.
Skin irritation due to high concentration of alcohol and poor skin penetration.
Microneedles
Minimally invasive and act by creating microscopic aqueous pores through which molecules can gain access to the dermal circulation without stimulating the dermal nerves or puncturing the dermal blood vessels [18] .
Obvious advantages over traditional patches in terms of delivery of actives. Possibility of delivering larger peptides, proteins and vaccines non-invasively through skin [18] .
Problems in processing & storage with sugar-based microneedle arrays; Thermal treatment during manufacture can restrict type of active loaded into arrays; Evaluation of biocompatibility of all microneedle materials with skin required; Regulatory issues should be considered due to innovativeness of delivery mode [19] .
Quantum dots (QDs)
These are small spherical or ellipsoidal particles, generally b20 nm on the major axis, with a metal core, an outer shell and various coatings or functional groups attached to the surface. Penetration of QDs has been studied in ex vivo rat, weanling pig and human skin. In contrast to the previous suggestions [65, 76] , little compelling evidence of quantum dot penetration in intact skin has been found to date. In 2006, Ryman-Rasmussen [63] used a range of QDs with different shapes and surface charges, applied to dermatomed weanling pig skin in buffers at pH 8.3 or 9.0. The QDs were found to be localized within the viable epidermis by 8 or 24 h, but none penetrated into the receptor of the flow-through cells used. The authors concluded that significant penetration through the stratum corneum and into the viable tissue was possible with these small particles. Later, Prow et al. [61] repeated some of ME = microemulsion; NLC = Nanostructured lipid carrier; NP = nanoparticle; PLGA = poly(lactic-co-glycolic acid); SLN = Solid lipid nanoparticles.
Ryman-Rasmussen's key experiments using excised human skin in order to examine the possibility that the penetration seen previously [63] may have been influenced by an immature barrier in weanling pig skin. The results, shown in Fig. 5 , indicate that at neutral pH none of the QDs penetrated beyond the stratum corneum and remained accumulated in the skin furrows. On the other hand, they did observe some penetration of the neutral PEG-coated particles to the viable epidermis at pH 8.3 [61] and suggested that the elevated pH may indeed cause a weakening of the stratum corneum barrier, in support of RymanRasmussen's findings [63] and others [77] . When 30 tape strips were applied to intact skin to physically disrupt the barrier, all QDs penetrated as far as the upper dermis by 24 h [61] . Zhang et al. [78] performed similar studies in rat skin using the same anionic QDs used by Ryman-Rasmussen, as well as with different QDs (nail shaped, PEG coated) in dermatomed weanling pig skin [79] . Interestingly, they saw no penetration of these QDs in intact rat or pig skin, nor did they detect penetration in flexed or tape stripped rat skin. There was, however, minimal QD penetration into abraded rat skin at 8 or 24 h. Taken together, these findings support the notion that while QDs may be able to penetrate a weakened or disrupted stratum corneum barrier to some extent, they are unlikely to penetrate intact human skin under normal conditions.
Effects of a stressed or compromised skin barrier
We have already seen that even under quite severe treatment such as tape stripping, the skin barrier is able to limit the penetration of small nanoparticles like QDs. In everyday life however, human skin is subject to a range of insults and stresses. For example, Tinkle et al. [64] have argued that if skin is exposed to particulate material during repetitive movement or mechanical stress, such as might occur in an industrial situation, or regularly walking barefoot, penetration of those particles may be enhanced. This led them to suggest that the skin was a route of exposure in industrial chronic beryllium disease, while further support came from observations of elephantiasis in individuals in certain regions in Africa, associated with penetration of clay particles through bare skin of their feet [80] . To test this, they investigated the effect of mechanical flexing on particle penetration in excised human skin and showed that 30-60 min of mechanical flexing led to the penetration of 0.5 and 1.0 μm FITC-dextran particles as far as the viable epidermis and occasionally to the dermis, as shown in Fig. 6 .
While these fluorospheres are far larger than the nanoparticles discussed above, Rouse et al. found that very small fullerene-substituted nanoparticles (about 3.5 nm) also penetrated into the dermis of dermatomed pig skin by 8 h after 60 min mechanical flexing [62] . This contrasts with the lack of penetration of the somewhat larger QDs through flexed rat skin noted above [78] .
Zinc oxide (ZnO) skin penetration
Nano-sized zinc oxide particles are commonly used in sunscreens to protect against the effects of UV radiation and are also subject to the same mechanical and repetitive stresses that are imposed upon skin during normal activities, as discussed above. This prompted concern about whether the nanoparticles could penetrate the skin barrier and access the viable epidermal cells [81] [82] [83] , particularly in view of in vitro evidence suggesting that ZnO nanoparticles are internalized by cultured human keratinocytes and cause cytotoxic and genotoxic responses [84] .
In an early in vitro study by Cross et al. in 2007 [56] , sunscreen formulations containing micronized ZnO nanoparticles (15-40 nm) were applied to human epidermal membranes in Franz cells for 24 h. Electron microscopy showed that the nanoparticles were confined to the surface and loose outer layers of the stratum corneum, with none detected in the lower stratum corneum or viable epidermis. Surprisingly however, they found evidence to suggest Zn penetration though the membrane, with a trend towards increased Zn levels in the receptor medium, detected by ICP-MS, although the differences were not significant. In an analogous in vivo study, Gulson et al. [57] also reported penetration of Zn through human skin. Sunscreens containing ZnO with N99% of the stable isotope 68 Zn, to distinguish from naturally occurring Zn, were applied to human volunteers under in use beach conditions over five consecutive days and small but significant amounts of 68 Zn were detected in blood and urine of volunteers by ICP-MS. Neither of these studies therefore provided direct evidence of intact ZnO penetration beyond the outer skin layers and it is likely that the Zn detected by ICP-MS was ionic Zn 2+ ions that penetrated following hydrolysis of ZnO on the skin surface. In support of the hydrolysis mechanism, the skin surface is known to be relatively acidic, particularly with moderate sweating as might be experienced in association with sunscreen use outdoors [85] and significant amounts of Zn 2+ have been shown to be released from 4 nm ZnO nanoparticles at pH 1, 3 and 6 [86] . More direct evidence of increased labile Zn 2+ penetration was recently reported by Holmes et al. [87] , after application of ZnO nanoparticles suspended in oil (capric caprylic triglycerides, or CCT) or water (pH 6 and 9). Zn 2+ was detected in the stratum corneum and viable epidermis by imaging the fluorescence due to the complex formed between Zn 2+ and the labile zinc selective probe Zinpyr-1, with the highest levels occurring with the pH 6 application. Notwithstanding the in vivo findings above [57] , it is generally accepted that passive penetration of ZnO nanoparticles into intact human skin is limited to the surface and upper layers of the stratum corneum [56, 88] . However, the question remains whether penetration can occur when the barrier is compromised, or when then skin is stressed or manipulated in normal activities. We have reported findings with in vivo ZnO nanoparticle applications in massage and flexing [59] , occlusion of the skin surface [1] , barrier disruption [1, 59, 89] , and skin conditions such as psoriasis and atopic dermatitis [89] , where both nanoparticle penetration and metabolic changes to endogenous fluorophores in skin (representing toxicity) were assessed by multiphoton tomography with fluorescence lifetime imaging (MPT-FLIM). The particles used in this work were characterised to be b200 nm in size and either bare, or with a siloxane coating. In none of these studies was there any significant evidence of penetration of nanoparticles into the viable epidermis or deeper. Unlike the evidence of microparticle penetration in excised human skin shown by Tinkle et al. [64] seen in Fig.   6 , MPT images of flexed in vivo human skin following application of bare (uncoated) and siloxane coated ZnO nanoparticles [59] show that all ZnO was confined to the skin surface, furrows and the upper layers of the stratum corneum (Fig. 7) .
Similar results were obtained with massage [59] (Fig. 7) and occlusion of the skin [1] (Fig. 8) No evidence of epidermal cytotoxicity due to effects of ZnO on NAD(P)H and FAD fluorescence lifetimes was seen with any of these treatments [1, 59] . Similarly, Fig. 9 shows that ZnO nanoparticles applied to psoriatic lesions in human patients also fail to penetrate into the viable epidermis and remain largely accumulated in the furrows.
In other work examining nanoparticle penetration with a compromised skin barrier, Monteiro-Riviere et al. applied ZnO and titanium dioxide (TiO 2 ) products to the skin of UVB sunburnt pigs in vivo and in vitro [60] . They observed minimal penetration of ZnO and TiO 2 , only into the upper layers of the viable epidermis and found no evidence of systemic absorption.
While this evidence about safety of ZnO nanoparticles is fairly convincing, particularly for intact skin, it should be recognised that the results obtained for compromised skin in relatively common conditions like psoriasis and atopic dermatitis, or in sunburn, are limited. Further work in this area is warranted, but the enormous benefits of sunscreens in protecting against skin cancer should not be overlooked when assessing the potential risks of nanoparticle application to the skin. Relevant to this debate is a recent study by Ryu et al. [90] , who applied up to 1000 mg/kg of a suspension of 29 nm ZnO nanoparticles to the skin of rats daily for 90 days. No evidence of toxicity was found, based on clinical examination, haematology, blood and urine biochemistry and histological analysis of tissues. ZnO accumulation in the liver, intestines and faeces was thought to be due to ingestion.
Follicular delivery of nanoparticles
In deliberate attempts to promote skin delivery, the Lademann group has used massage to deliver nanoparticles of optimal sizes of 300-600 nm deep within the follicle. They showed that although an intact and relatively impermeable stratum corneum similar to that of the interfollicular epidermis covers the acroinfundibulum (the upper portion of the follicle as it enters the epidermis), this barrier is interrupted in the lower follicular infundibulum. The corneocytes in this area appear smaller and crumbly, suggesting that the skin barrier is permeable and provides an opportunity for interactions between topically applied compounds and the hair follicle epithelium [91] . Interestingly, this particle size matches the cuticula thickness on human (530 nm) and porcine (320 nm) hair, so the suggestion is that hair movement during massage allows the cuticulae to engage with the matching particles like a geared system, driving them deep into the follicle [66, 92, 93] . The ability to target nanoparticles to different depths in the follicle, depending on their size may allow treatment of different site-specific conditions. In addition, 320 nm particles have been shown to reside in the follicle for up to 10 days, indicating that the follicle could act as a reservoir for long term storage and release of drugs delivered in association with nanoparticles [94] . Trauer et al. [95] also used massage and occlusion to enhance follicular penetration of liposomal systems in ex vivo human skin. Massage was found to enhance the follicular penetration of rigid and flexible liposomes significantly, while occlusion was favoured only for the rigid liposomes.
Vogt et al. [96] , also from the Lademann group in Berlin, showed that after cyanoacrylate stripping to remove the contents of human vellus hair follicles followed by massage, 40 nm particles could be targeted deep within the follicle and through the follicular epithelium, to be internalized by Langerhans cells surrounding the follicles [97] , whereas 750 and 1500 nm particles remained in the infundibulum and were not internalized, as shown in Fig. 10 .
These workers suggested that the small nanoparticles could be an efficient delivery system for vaccine delivery to cutaneous antigen-presenting cells illustrated in Fig. 2 . They expanded these concepts in recent work [98] , showing that larger 200 nm nanoparticles also penetrated deeply with massage into human vellus and intermediate hair follicles after a single cyanoacrylate treatment to remove follicular contents. Moreover, the cyanoacrylate treatment was associated with clear signs of activation and migration of dendritic cells indicated by retraction of dendrites, reduction of LC numbers in the epidermis with concomitant increases in the dermis surrounding the follicles and expression of activation markers. Their work suggests that follicular delivery combined with immune activation would be a viable technique to promote uptake of topical antigens.
Other nanodelivery systems investigated for follicular delivery include lipid nanocarriers [95, [99] [100] [101] [102] [103] [104] , nanoemulsions [105] [106] [107] and polymeric vesicles [108] [109] [110] [111] . The Hoffman group in San Diego used a phosphatidylcholine-based liposome system to deliver proteins, genes, melanin and small molecules selectively to the pilosebaceous unit in mice, with negligible amounts detected in the epidermis, dermis or systemic circulation [101] [102] [103] [104] . These nanosystems will be discussed in more detail below, with regard to delivery through the stratum corneum barrier.
Colloidal nanocarrier systems
These have been increasingly exploited for dermatological, cosmetic and personal care applications. Common colloidal nanosystems include the liquid emulsions (microemulsions and nanoemulsions) (NE), solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and advanced nanovesicles such as flexible and ultraflexible liposomes. These formulations can offer increased efficacy and targeted delivery, improved bioavailability and stability of the active, reduced irritancy, and facilitate the formulation of lipophilic, poorly water-soluble compounds.
Emulsions
Microemulsions were first described scientifically by Hoar and Schulman in 1943 [112] . They noted that coarse macroemulsions stabilized with an ionic surfactant became transparent on addition of a medium chain length alcohol, a co-surfactant. After originally referring to these systems as hydrophilic oleomicelles or oleophilic hydromicelles, Schulman et al. introduced the term 'microemulsion' in 1959 [113] . It was not until the 1980s that the potential use of microemulsions as topical formulations for skin delivery was explored [114, 115] .
Nanoemulsions (NE) for skin delivery
Nanoemulsions are dispersions of oil and water phases stabilized by surfactants, with mean droplet diameter in the submicron range [116, 117] . They can be formed by high-energy and low-energy emulsification techniques [118] and typically contain a relatively low percentage of surfactant [119] . The small droplet size results in a kinetically stable system that resists destabilization due to gravitational separation, flocculation and coalescence [119] , and is transparent or translucent. The low surfactant content offers advantages in topical application with reduced irritancy to the skin. The small droplet size provides a large surface area and uniform distribution on the skin, good occlusiveness, film formation, aesthetic qualities and skin feel [120, 121] . NEs have wide application in the pharmaceutical and cosmetic industries for indications including inflammation, anti-aging, moisturisation and beauty [122] . They have particular utility in the management of chronic skin diseases such as atopic dermatitis or dry skin, to provide skin protection and hydration, without irritating or weakening the skin barrier [123] . NEs can enhance permeation into the skin by a number of mechanisms. First, they provide a high solubilization capacity for both lipophilic and hydrophilic compounds, thereby increasing the loading capacity and dose application of the formulation. Second their large surface area and good skin contact, coupled with their occlusive nature ensures good surface contact with the stratum corneum surface. Third, their oil and surfactant components may have a direct permeation enhancement effect on the stratum corneum lipid structure. A recent review provides a summary of the dermatological applications of NEs [122] .
We showed significantly enhanced flux of the hydrophilic caffeine and lipophilic naproxen across human epidermis in vitro [34] . The NE oil phase was composed of the skin penetration enhancers oleic acid or eucalyptol with the aim of investigating a synergistic effect of the increased surface area and contact with the skin, enhanced solubility and direct chemical enhancement effects of the oil excipients within the stratum corneum. There was only a modest increase in caffeine solubility within the stratum corneum, therefore the increase in skin diffusivity that contributed to the maximum flux enhancement resulted primarily from the direct effect of the NE excipients reducing the diffusional resistance for caffeine penetration within the stratum corneum. In contrast, increased flux of the lipophilic naproxen was primarily due to formulation-increased solubility of naproxen in the stratum corneum, with only a modest increase in diffusivity.
Lipid-based colloidal nanosystems

Solid lipid nanoparticles (SLN)
SLN were developed in parallel in Germany [124] and Italy [125] , in the early 1990s. They are composed of lipids, lipid-like materials or a mixture with a diameter from 10 nm to 10 μm, are solid at ambient temperature and able to incorporate active agents into their solid core for various delivery applications (e.g. parenteral, enteral, pulmonary and topical) resulting in a controlled release over a long period of time [126] . They are normally prepared by high-pressure homogenization and offer the opportunity to formulate hydrophobic actives such as vitamin A, vitamin E [127] and coenzyme Q10 in cosmetically elegant products, rather than an ointment with poor aesthetic qualities and consumer acceptability. They can also increase the stability of compounds such as retinol that are prone to decomposition in the presence of light and oxygen [55, 128] and provide controlled delivery of actives to the skin. For example Zhang et al. [129] showed higher stratum corneum deposition but lower flux of aconitine from SLN compared with a nanoemulsion emulsion of similar sized vesicles (70-90 nm). SLNs form a film on the skin surface that combines with the skin lipid film to reduce water loss, increase skin hydration and help protect the barrier function of the stratum corneum [130, 131] . Good skin adherence is particularly useful in sunscreen products where wash off due to sweating and bathing can lead to unforeseen sunburn. Enhanced stratum corneum permeation is attributed to multiple mechanisms: prolonged contact with the skin surface; the occlusive nature of the SLN formulation hydrating the skin [8] ; and interaction between formulation lipids and stratum corneum lipids facilitating permeation of lipid soluble compounds. Küchler et al. [132] used scanning electron microscopy to show the loss of SLN platelet structure 2 h after administration on the surface of pig skin. Evidence of the interaction between cetyl palmitate SLN formulation lipids and stratum corneum lipids were demonstrated by shifts of phase transition temperature (differential scanning calorimetry) and stretching bands (Fourier transform infrared spectroscopy) [133] . Zhang et al. [134] observed that this interaction was highly formulation dependent as prolonged and localized delivery of betamethasone 17-valerate could be achieved with monostearin SLN but not with other lipids such as beeswax. The cationic phospholipids 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and dioleoylphosphatidylethanolamine (DOPE) provide the potential for charge interaction with the negatively charged skin surface. Highly positively charged (51 mV) SLN using DOTAP, DOPE, Tween 20 as surfactants, tricaprin as a solid lipid core, and encapsulating plasma DNA, showed enhanced in vitro permeation into mouse skin and expression of mRNA in vivo in mice after topical application [135] .
Nanostructured lipid carriers (NLC)
The second generation of SLN, nanostructured lipid carriers (NLC) appeared in 1999 with the filing of the US patent by the German company PharmaSol GmbH. These nanoparticles showed improved drug loading and stability of long-term incorporation [136] . As with liposomes, the introduction of NLC was into the cosmetic market, aided by lower regulatory hurdles, with the launch of Cutanova Cream Nano Repair Q10 and Intensive Serum NanoRepair Q10 by Dr. Rimpler GmbH (Germany) in October 2005 [137, 138] .
NLC are composed of a fluid lipid phase embedded into a solid lipid matrix [126] or localized at the surface of solid platelets and the surfactant layer [139] . The lipids spatial structure allows greater drug loading and better stability compared to SLN [140] . For example the sunscreen loading capacity of 70% in NLC compared to 10-15% in SLN, allows the development of suncare products with higher sun protection factor (SPF) [141] . Chen et al. [142] showed improved stability of Coenzyme Q10 in NLCs compared to an emulsion or ethanol formulation (decrease of 5.59%, 24.61% and 49.74% respectively). The accumulation of Co Q10 in rat epidermis from the optimized Q10-NLC formulation (particle size 151.7 ± 2.31) was also 10 times greater than from the emulsion. NLC and SLN are reported to have a similar mechanism of permeation enhancement, via occlusion and mixing between the formulation and stratum corneum lipids, however the liquid lipid component in NLC increases solubilization and thereby loading of the active, resulting in greater skin deposition. Improved skin deposition has been demonstrated for a number of compounds including tacrolimus [143, 144] , psoralen [145] , methotrexate [146] , miconazole nitrate [147] , fluocinolone acetonide [148] and 5-amino levulinic acid [149] .
Singh's group has investigated surface modification for enhancing delivery and targeting of NLC to the skin [150] [151] [152] . NLC with the cellpenetrating peptide transactivating transcriptional activator (TAT-NLC) showed greater epidermal deposition of a fluorescent probe and the lipophilic drug celecoxib, compared to control NLC, that were located mainly in the hair follicles following topical administration to rat skin in vitro [150, 151] . They subsequently showed that surface modification of the NLC with a cell penetrating peptide containing 11 arginines had significantly greater permeation enhancing ability compared to other polyarginines and TAT peptides [152] .
Flexible nanovesicles
Flexible liposomes or vesicles are composed of materials that will aggregate into bilayer structures but have the ability to deform in shape. Cevc's original Transfersomes® were composed of phosphatidylcholine with the surfactant sodium cholate included as an 'edge activator' to confer flexibility, allowing the spherical shape to elongate and potentially squeeze through narrow channels relative to the their spherical diameter [153] [154] [155] . Based on the principles of conferring flexibility to the bilayer structure and/or incorporating components that are known to act as skin penetration enhancers, various vesicle compositions have been developed and their skin permeation quantified. These include ethosomes (phospholipids with a high proportion of ethanol) [13, [156] [157] [158] [159] [160] , niosomes (flexible non-ionic surfactant vesicles) [161] [162] [163] [164] [165] [166] , invasomes (phosphatidylcholine, ethanol and a mixture of terpene penetration enhancers) [167] [168] [169] , SECosomes (surfactant, ethanol and cholesterol) [14, 170] and PEVs (penetration enhancer containing vesicles) [171, 172] . Many different components including chemical penetration enhancers have been investigated including oleic acid, limonene [171, 173] , propylene glycol [156, 174] , glycerol [175] , transcutol [176] . Flexible nano-vesicles have shown effective skin penetration enhancement of many compounds that have very poor passive permeation. For example, Dragicevic-Curic and Fahr [177] recently reviewed the area of flexible vesicle delivery for topical photodynamic therapy (PDT), which involves the delivery of a photosensitizer compound to cancer cells within the skin, followed by light activation to kill the cells. Photosensitizer compounds, such as 5-amino levulinic acid and temoporfin (mTHPC), have very poor passive permeation, and the aim in PDT is to target the skin whilst minimising systemic uptake. Dragicevic-Curic et al. [178] showed that an enhancement ratio of 3.4 and 2.2 for mTHPC delivery into the skin could be achieved with invasomes (phosphatidylcholine, ethanol and terpenes) compared to conventional liposomes and ethanol containing vesicles respectively. They also showed that the choice of terpene significantly influenced skin deposition, with cineole being superior to limonene, citral and mixtures of these terpenes. They also showed that the surface charge of flexible liposomes (composed of neutral, anionic and cationic lipids, and polysorbate 20 surfactant) affects the physicochemical properties, stability and permeation in human epidermal membranes in vitro [169] . Skin deposition of mTHPC was enhanced by all flexible vesicles in the following order: cationic N neutral N anionic N conventional liposomes, with the suggestion that the cationic lipids most effectively interact with the negatively charged stratum corneum. In the work by Geusens et al. (Fig. 11) , cationic ultra-flexible 58 nm nanosomes (SECosomes) were shown to deliver siRNA into the viable epidermis with deposition monitored by multiphoton tomography in combination with fluorescence lifetime imaging microscopy (MPT-FLIM) [14] . SECosomes were composed of the cationic lipid 1,2-dioleoyl-3-trimethylammonium propane chloride (DOTAP), cholesterol, sodium cholate and 30% ethanol. Images showed human epidermal delivery of siRNA after 1 h and NADH lifetime changes in the epidermal tissue, that suggest cell penetration of the fluorescent siRNA.
Bracke et al. [170] have applied the SECosome approach to the delivery of siRNA to target human beta defensin (hBD-2), which is highly upregulated in psoriasis and has been defined as a biomarker for the condition. DEFB4-siRNA-containing SECosomes, targeting hBD-2, were applied in a bioengineered skin-humanized mouse model for psoriasis. The authors reported a significant improvement in the psoriatic phenotype, normalization of the skin architecture and a reduction in the number and size of blood vessels in the dermal compartment. SECosome treatment lead to recovery of transglutaminase activity, filaggrin expression and stratum corneum appearance that was similar to normal regenerated human skin. Further support to the work of Geusens was reported in 2016 by Dorrani et al. [179] , who showed that passive application of small (~75 nm) liposome:siRNA complexes could deposit siRNA as deeply as the upper dermis of human cadaver skin. Significantly, no labeled liposomes or siRNA were detected in the receptor compartment of the Franz cells in which the study was done, suggesting that the lipoplexes did not travel beyond the dermis but deposited their cargo locally. Furthermore, they were able to show that the lipoplexes could internalize into melanoma cells in culture, knock down BRAF expression and inhibit melanoma cell proliferation.
There are a number of proposed mechanisms by which nanovesicle systems enhance skin permeation. One mechanism is that the vesicles disintegrate on the skin surface and their components penetrate into the stratum corneum, mixing with and modifying the lipid bilayers and thereby indirectly enhancing permeation [180] . Many of the oil and surfactant components of flexible vesicles are known to disrupt the stratum corneum lamellae to facilitate skin transport [181] . Another theory proposed by Cevc [16] , and supported by other colleagues [182] , is that the intact flexible vesicles can penetrate into and through the stratum corneum due to the transepidermal osmotic gradient, carrying their payload into the skin. The composition of the vesicle must be such that the molecules within the vesicle bilayer can adjust to allow the vesicle to deform to the shape of a pore within the stratum corneum. This is achieved because edge-active molecules such as surfactants or shortchain alcohols can concentrate at the sites of greatest curvature [17, 183] . However, recent evaluations of vesicle skin interactions using the high resolution technologies of multiphoton excitation fluorescence microscopy imaging and cross correlation-raster image correlation spectroscopy (CC-RICS) [180] and stimulated emission depletion microscopy (STED) and CC-RICS [184] have failed to show evidence of intact vesicles within the skin. STED provides image resolution to 20 nm, whilst CC-RICS allows tracking of two fluorescent probes so that intact vesicles can be resolved. In the latter study, vesicles and flexible vesicles incorporating sodium cholate (mean diameter 96 nm) were applied unoccluded to freshly excised human skin for 4-8 h, then imaged. Images showed that for both vesicles and flexible vesicles, a large number of intact vesicles remained at the skin surface, particularly in the skin furrows, with very few intact vesicles in the stratum corneum. A much higher proportion of vesicles than flexible vesicles remained intact on the skin surface, and there was significantly more fluorescent probe in the deeper layers of the stratum corneum for the flexible vesicles. As the fluorescent signal was not associated with any vesicle-like shape, the authors concluded that the flexible vesicle components were contributing to the penetration enhancement. They also suggested that the penetration of intact flexible vesicles shown in earlier studies was due to the choice of mouse skin with its thinner stratum corneum.
Physical enhancement and combinational methods for facilitated-delivery
Normally, when the stratum corneum is intact and the skin barrier is uncompromised, dermal and transdermal delivery is limited to molecules that are relatively lipophilic, small and uncharged. Consequently, many potentially useful therapeutic peptides, proteins, vaccines, gene fragments or drug-carrying particles are excluded. In efforts to extend the range of potential skin deliverables, various active technologies that apply physical forces to overcome the skin barrier, utilizing acoustic, electrical, or electromagnetic energy (e.g. laser radiation or radiofrequencies) and high pressure have been extensively investigated over several decades [185, 186] . Techniques include iontophoresis, sonophoresis, thermal and radiofrequency ablation, laser assisted delivery and jet propulsion systems, as well as microneedles, which directly breach the stratum corneum. However, despite this level of research interest, FDA approvals for device assisted transdermal delivery of molecules have been few (5 between 1979 and 2013) [187] . Furthermore, commercial development of transdermal devices has mainly been in the area of iontophoresis (e.g. Ionsys® and Zecuity®, both FDA-approved for fentanyl and sumatriptan delivery respectively and others). A few products used other technologies such as thermal ablation (e.g. the PassPort® patch developed by Altea Therapeutics, later acquired by Nitto Denko Technicla Corp.), radiofrequency ablation (e.g. the ViaDerm® system by TransPharma Medical Ltd.), lasers (e.g. the EpitureTM system developed by Norwood Abbey), jet propulsion (e.g. Mini-JectTM by Valeritas and the PowderJect® system) and direct heat application (Controlled Heat-Assisted Drug Delivery (CHADD™) technology). The SonoPrep® system, developed by Sontra, used low frequency ultrasound to deliver lidocaine for local analgesia. This was the only low frequency sonophoresis system on the market but has since been withdrawn.
Further enhancement and even synergistic transdermal delivery has been achieved with a combination of techniques, including an active technology with chemical permeation enhancers [188] or two active technologies [189] . Of particular interest is the combination of microneedle delivery with active technologies such as iontophoresis [190] or sonophoresis [191] . Here, the goal is to use the microneedles to accurately place the deliverable at a specific target site and to use the second active technology to enhance its release and distribution. Donnelly et al. [190] showed enhanced delivery of peptides and proteins with the combination of iontophoresis and hydrogel-forming microneedle arrays and suggested that the technique may more useful for macromolecules than small molecules which are already delivered efficiently by microneedles alone. While the use of combination technologies may offer enhanced delivery with improved control over delivery rates, along with some degree of specific targeting in the case of microneedles, they are also currently associated with greater complexity, cost and difficulty of use. If they are to achieve widespread acceptance and use, it will be necessary to harness advances in device design and fabrication to make them more refined and inexpensive.
Safety and adverse effects
As discussed in Section 3, there is concern that penetration of biopersistent solid nanoparticles into the skin could lead to damage to viable epidermal cells or accumulation in secondary organs following biodistribution [70] . Examples of such materials include gold, silver, metal oxides such as titanium dioxide and zinc oxide, quantum dots, fullerenes and carbon nanotubes. Consequently, rigorous risk assessment is required for these [192] . Also falling into the biopersistent category are the environmental hazards such as clay particles absorbed though skin of bare feet [80] or skin-absorbed beryllium [64] . There is less concern over colloidal nanosystems such as emulsions and lipid-based materials because these are likely to be biodegradable on application to the skin, although the molecular products will still be assessed in the usual way for irritancy and cytotoxicity. For example, Todosijević et al. [193] used changes in erythema index, skin hydration and TEWL to assess the skin irritancy of different microemulsion formulations containing natural and synthetic non-ionic surfactants for delivery of a model NSAID and showed that irritancy was strongly associated with the presence of Polysorbate 80 and Transcutol P. Gürbüz et al. [194] assessed the cytotoxicity of microemulsions for isotretinoin delivery using the MTT assay with a mouse fibroblast cell line, comparing the microemulsions to sodium lauryl sulfate (SLS) as a positive control. Standard techniques to assess cell viability with mouse or human cell lines have also been used for lipid-based vesicles [195, 196] and ultraflexible liposomes [14, 197] . Raju et al. used multiphoton imaging of fluorescence following staining by acridine orange and ethidium bromide to demonstrate cell viability or death in response to interventions by delivery devices such as gene guns [198] . These workers showed that ballistic delivery of gold microparticles coated with DNA vaccine at densities of 0.16, 1.35 and 2.72 particles/m 2 to freshly excised mouse ear skin resulted in cell death rates of 3.96, 45.91 and 90.52% respectively. The results raised questions about the safety of this technique and the authors suggested that successfully optimized transfection with this device would require a compromise between the payload density and the inevitable level of cell death.
Future developments
We are constantly facing new challenges in skin delivery and as we have seen, extensive research is being undertaken to develop novel and improved delivery systems. For example, a recent sunscreen formulation uses bioadhesive nanoparticles with limited skin penetration to prevent epidermal cell exposure to potentially toxic chemical UV filters, at the same time providing enhanced UV protection [199] . As Vogt et al. have recently pointed out, a worthwhile nanodelivery system should offer significant advantages, such as easier application, reduced systemic absorption and enhanced selectivity to diseased skin or specific cell populations, compared to more traditional methods [200] . We would add that, in our view, the development of dermal and transdermal nanodelivery systems should be driven by a clinical or therapeutic need, rather than by the availability of advanced technology. One such clinical need is the long sought after, but highly elusive goal of non-invasive insulin delivery. Nanodelivery strategies being explored for this hydrophilic macromolecule include a patch consisting of a polymeric nanotube backbone to which insulin is electrostatically bound [201] . An electric potential is then applied to release the bound insulin. The potential is also hypothesized to drive the drug into the skin, analogous to iontophoresis. Another important clinical application of nanodelivery systems is likely to be needle free transcutaneous immunization, particularly by the hair follicle route [202] .
The next generation of nanocarriers will be designed to release their drug payload in response to certain chemical, physical or biological stimuli, allowing much greater precision in delivery to particular targets-the so-called "Smart" nanosystems. Much work is already being carried out on intravenous or orally administered drug or gene delivery systems that are responsive to temperature, UV or IR radiation, ultrasound or pH [203] . For example, smart nanocarriers that can accumulate in tumors after intravenous injection have been developed which combine pH-triggered doxorubicin release and near infrared light-triggered photosensitization to provide dual chemotherapy and photodynamic therapy [204] . New skin penetrating nanocarriers containing similar triggers will no doubt be developed to deliver deeper, faster and better-targeted skin cancer therapy than that currently available with creams containing aminolevulinic acid (ALA) or its methyl ester (MAL).
As we have already seen, the Lademann group has explored follicular delivery of nanoparticles and hypothesized that these appendages may act as a reservoir for a drug payload [92] . Up to now, the difficulty has been how to initiate and control drug release, rather than relying on passive diffusion. In recent work [205] they are now exploring smart nanoparticles for follicular delivery that are designed to release a drug after the application of specific stimuli. Three nanoparticle systems were developed, where model drug release occurred by passive diffusion through a porous surface, in response to enzymatic degradation of the encapsulating particle and after photoactivation by infrared radiation. Deep follicular penetration of the model drugs, as well as uptake by sebaceous glands was seen with the latter two active release mechanisms.
Conclusion
Our observation is that nanodelivery systems show great promise, provided that they are optimally matched to their designed purpose, rather than simply being seen as "one technology fits all" applications. With this in mind, it should also be recognised that nanosystems may not necessarily be the most efficient way to solve a particular problem. Vogt et al. [200] recently alluded to this, citing the example of treating scalp diseases, where nanoparticles may not be required for follicular penetration. However, the evolutionary development in these systems is likely to continue, with a greater focus on solving difficult skin delivery problems, by developing smart materials to deliver peptides, proteins and genetic material with accurate targeting to specific cell populations. As nanosystems are refined, emphasis will need to be placed on those that can be translated to clinical application and which provide significant economic and patient benefits.
